AGE, RAGE, and ROS in Diabetic Nephropathy

Seminars in Nephrology

Volumn 27, Issue 2, 2007, Pages 130-143

  Tan, Adeline L Y ^a   Forbes, Josephine M ^a   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

advanced glycation end products; Diabetes mellitus; diabetic nephropathy complications; oxidative stress; receptors

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR 1; ADVANCED GLYCATION END PRODUCT RECEPTOR 2; ALAGEBRIUM; ALPHA TOCOPHEROL; ALT 946; AMINOGUANIDINE; ANTIDIABETIC AGENT; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; MEMBRANE RECEPTOR; NITECAPONE; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG MECHANISM; GLYCATION; GLYCOSYLATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RENAL PROTECTION; TOXICITY;

ANIMALS; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 34047248203     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.01.006     Document Type: Article

References (89)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
4. Bohlender J.M., Franke S., Stein G., et al. Advanced glycation end products and the kidney. Am J Physiol 289 (2005) F645-F659
5. Goldberg T., Cai W., Peppa M., et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104 (2004) 1287-1291
6. Cai W., Gao Q.D., Zhu L., et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 8 (2002) 337-346
7. Miyata T., Ueda Y., Horie K., et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53 (1998) 416-422
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
9. McRobert E.A., Gallicchio M., Jerums G., et al. The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. J Biol Chem 278 (2003) 25783-25789
10. Lu C., He J.C., Cai W., et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 101 (2004) 11767-11772
11. Bierhaus A., Humpert P.M., Morcos M., et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83 (2005) 876-886
12. Bierhaus A., Chevion S., Chevion M., et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 46 (1997) 1481-1490
13. Wautier J.L., Zoukourian C., Chappey O., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97 (1996) 238-243
14. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
15. Wendt T.M., Tanji N., Guo J., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162 (2003) 1123-1137
16. Morcos M., Sayed A.A., Bierhaus A., et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51 (2002) 3532-3544
17. Geoffroy K., Wiernsperger N., Lagarde M., et al. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J Biol Chem 279 (2004) 34343-34352
18. Tanji N., Markowitz G.S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11 (2000) 1656-1666
19. Soulis T., Thallas V., Youssef S., et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40 (1997) 619-628
20. Li J., and Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272 (1997) 16498-16506
21. Soulis-Liparota T., Cooper M.E., Dunlop M., et al. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38 (1995) 387-394
22. Forbes J.M., Soulis T., Thallas V., et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44 (2001) 108-114
23. Tsuchida K., Makita Z., Yamagishi S., et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42 (1999) 579-588
24. Cohen M.P., Masson N., Hud E., et al. Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp Nephrol 8 (2000) 135-143
25. Cohen M.P., Sharma K., Jin Y., et al. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J Clin Invest 95 (1995) 2338-2345
26. Forbes J.M., Thallas V., Thomas M.C., et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17 (2003) 1762-1764
27. Flyvbjerg A., Denner L., Schrijvers B.F., et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53 (2004) 166-172
28. Yamamoto Y., Kato I., Doi T., et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108 (2001) 261-268
29. Vlassara H., Striker L.J., Teichberg S., et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91 (1994) 11704-11708
30. Yan S.D., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269 (1994) 9889-9897
31. Miura J., Yamagishi S., Uchigata Y., et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complications 17 (2003) 16-21
32. Beisswenger P.J., Makita Z., Curphey T.J., et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44 (1995) 824-829
33. Monnier V.M., Bautista O., Kenny D., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48 (1999) 870-880
34. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348 (2003) 2294-2303
35. Wautier M.P., Massin P., Guillausseau P.J., et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 29 (2003) 44-52
36. Kilhovd B.K., Giardino I., Torjesen P.A., et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52 (2003) 163-167
37. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325 (1991) 836-842
38. Vlassara H., and Palace M.R. Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 70 (2003) 232-241
39. He C.J., Koschinsky T., Buenting C., et al. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 7 (2001) 159-168
40. He C.J., Zheng F., Stitt A., et al. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int 58 (2000) 1931-1940
41. Liu H., Zhu L., Zheng F., et al. Overexpression of AGE-Receptor-1 (AGE-R1) in mice prevent AGE accumulation and delays diabetic renal injury. Diabetes 54 (2005) A21-B
42. Pugliese G., Pricci F., Leto G., et al. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 49 (2000) 1249-1257
43. Pugliese G., Pricci F., Iacobini C., et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 15 (2001) 2471-2479
44. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82 (2002) 47-95
45. Johansen J.S., Harris A.K., Rychly D.J., et al. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4 (2005) 5
46. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787-790
47. Kaneda K., Iwao J., Sakata N., et al. Correlation between mitochondrial enlargement in renal proximal tubules and microalbuminuria in rats with early streptozotocin-induced diabetes. Acta Pathol Jpn 42 (1992) 855-860
48. Batandier C., Leverve X., and Fontaine E. Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J Biol Chem 279 (2004) 17197-17204
49. Oliveira P.J., Esteves T.C., Seica R., et al. Calcium-dependent mitochondrial permeability transition is augmented in the kidney of Goto-Kakizaki diabetic rat. Diabetes Metab Res Rev 20 (2004) 131-136
50. James A.M., and Murphy M.P. How mitochondrial damage affects cell function. J Biomed Sci 9 (2002) 475-487
51. Maritim A.C., Sanders R.A., and Watkins III J.B. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17 (2003) 24-38
52. Touyz R.M., Chen X., Tabet F., et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90 (2002) 1205-1213
53. Kitada M., Koya D., Sugimoto T., et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52 (2003) 2603-2614
54. Forbes J.M., Cooper M.E., Thallas V., et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 (2002) 3274-3282
55. Onozato M.L., Tojo A., Goto A., et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61 (2002) 186-194
56. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49 (2000) 1939-1945
57. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 280 (2001) E685-E694
58. Aliciguzel Y., Ozen I., Aslan M., et al. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 142 (2003) 172-177
59. Craven P.A., Phillips S.L., Melhem M.F., et al. Overexpression of manganese superoxide dismutase suppresses increases in collagen accumulation induced by culture of mesangial cells in high-media glucose. Metabolism 50 (2001) 1043-1048
60. Fu M.X., Knecht K.J., Thorpe S.R., et al. Role of oxygen in cross-linking and chemical modification of collagen by glucose. Diabetes 41 Suppl 2 (1992) 42-48
61. Suzuki D., Miyata T., Saotome N., et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10 (1999) 822-832
62. Odetti P., Traverso N., Cosso L., et al. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia 39 (1996) 1440-1447
63. Jiang J.M., Wang Z., and Li D.D. Effects of AGEs on oxidation stress and antioxidation abilities in cultured astrocytes. Biomed Environ Sci 17 (2004) 79-86
64. Yim M.B., Yim H.S., Lee C., et al. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci 928 (2001) 48-53
65. Lal M.A., Brismar H., Eklof A.C., et al. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 61 (2002) 2006-2014
66. Fujii J., Myint T., Okado A., et al. Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. Nephrol Dial Transplant 11 Suppl 5 (1996) 34-40
67. Koschinsky T., He C.J., Mitsuhashi T., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94 (1997) 6474-6479
68. Lin R.Y., Choudhury R.P., Cai W., et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168 (2003) 213-220
69. Zheng F., He C., Cai W., et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 18 (2002) 224-237
70. Vlassara H., Cai W., Crandall J., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99 (2002) 15596-15601
71. Peppa M., Uribarri J., Cai W., et al. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 43 (2004) 690-695
72. Uribarri J., Peppa M., Cai W., et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42 (2003) 532-538
73. Khalifah R.G., Baynes J.W., and Hudson B.G. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257 (1999) 251-258
74. Coughlan M.T., Cooper M.E., and Forbes J.M. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?. Ann N Y Acad Sci 1043 (2005) 750-758
75. Brownlee M., Vlassara H., Kooney A., et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 (1986) 1629-1632
76. Nilsson B.O. Biological effects of aminoguanidine: an update. Inflamm Res 48 (1999) 509-515
77. Degenhardt T.P., Alderson N.L., Arrington D.D., et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61 (2002) 939-950
78. Soulis T., Cooper M.E., Vranes D., et al. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50 (1996) 627-634
79. Bolton W.K., Cattran D.C., Williams M.E., et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24 (2004) 32-40
80. Freedman B.I., Wuerth J.P., Cartwright K., et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20 (1999) 493-510
81. Forbes J.M., Thorpe S.R., Thallas-Bonke V., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16 (2005) 2363-2372
82. Cooper M.E., Thallas V., Forbes J., et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 43 (2000) 660-664
83. Lal M.A., Korner A., Matsuo Y., et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 49 (2000) 1381-1389
84. Ting H.H., Timimi F.K., Boles K.S., et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97 (1996) 22-28
85. Bursell S.E., Clermont A.C., Aiello L.P., et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22 (1999) 1245-1251
86. Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 (1996) 781-786
87. Yusuf S., Dagenais G., Pogue J., et al., The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 154-160
88. Hausse A.O., Aggoun Y., Bonnet D., et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87 (2002) 346-349
89. Piconi L., Quagliaro L., Assaloni R., et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 22 (2006) 198-203